MedTrace Logo

Observational Study in Real Life to Describe the Libicare® Effectiveness in Female Sexual Dysfunction.

NCT04124640 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 185

Last updated 2022-12-02

No results posted yet for this study

Summary

The decrease or absence sexual desire and arousal is the alteration of the sexual sphere that women most commonly refer to in adulthood and old age. Many women can refer a decrease or absence of desire and / or arousal without having the disorder typified in the DSM-5, but that can cause discomfort, worry and relationship problems in their day to day. Libicare® is a food supplement whose ingredients could have positive effects on the improvement of sexual function in women with low desire and arousal levels. The main ingredients of Libicare® are:

* Trigonella Foenum-graecum (Trigonella) (1)
* Tribulus Terrestris (Tribulus) (2)
* Turnera Diffusa (Damiana) (3)

Conditions

  • Female Sexual Dysfunction

Interventions

OTHER

Patients' data (baseline characteristics, clinical and outcomes) from routine care visits

Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.

Sponsors & Collaborators

  • Procare Health Iberia S.L.

    lead INDUSTRY

Principal Investigators

  • Josep Combalia, MD · Procare health Iberia

  • Santiago Palacios · Instituto Palacios de Salud y Medicina de la Mujer.

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-29
Primary Completion
2020-12-31
Completion
2021-11-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04124640 on ClinicalTrials.gov